Xospata (gilteritinib) FDA Approval History | 合法藥品大搜索
2018年11月28日—Xospata(gilteritinib)isaFLT3/AXLkinaseinhibitorindicatedforthetreatmentofpatientswhohaverelapsedorrefractoryacutemyeloid ...
2018年11月28日 — Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid ...
Gilteritinib FDA NCT02421939 Xospata fda ADMIRAL trial XOSPATA Midostaurin FDA Midostaurin 仿單 TIBSOVO Gilteritinib FDA Xospata fda NCT02421939 ADMIRAL trial Midostaurin FDA TIBSOVO Midostaurin 仿單 XOSPATA PRESCRIBING information midostaurin fda approval aml gilteritinib fda approval RYDAPT Midostaurin fever Midostaurin ema quizartinib fda approval 胃莫潰致癌 potassium cresolsulfonate機轉 "聯邦"力確多寧注射液１公絲/公撮副作用 得膚寶軟膏藥局 抗敏液哪裡買 勝克敏液 價錢 ２－（４異丁基苯）丙酸 斷血炎ptt
FDA Approval Summary | 合法藥品大搜索
FDA approves gilteritinib for relapsed or refractory acute ... | 合法藥品大搜索
2018年11月28日 — On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US Inc.) for treatment of adult ... Read More
FDA approves addition of survival data to gilteritinib label for ... | 合法藥品大搜索
On May 29, 2019, the Food and Drug Administration approved the addition of overall survival data in labeling for gilteritinib (XOSPATA, Astellas Pharma US, ... Read More
Gilteritinib | 合法藥品大搜索
由 S Dhillon 著作 · 2019 · 被引用 46 次 — Gilteritinib is approved in Japan for the treatment of relapsed or refractory AML with FLT3 mutation. Recently, it was also approved in the USA for the ... Read More
gilteritinib | 合法藥品大搜索
XOSPATA® (gilteritinib) tablets, for oral use. Initial U.S. Approval: 2018. WARNING: DIFFERENTIATION SYNDROME. See full prescribing information for complete ... Read More
Drug Approval Package | 合法藥品大搜索
2018年12月21日 — Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling. Read More
FDA Approval Summary | 合法藥品大搜索
由 ED Pulte 著作 · 2021 — On November 28, 2018, the FDA approved gilteritinib (Xospata; Astellas), a small-molecule FMS-like tyrosine kinase 3 (FLT3) inhibitor, ... Read More
Xospata (gilteritinib) FDA Approval History | 合法藥品大搜索
2018年11月28日 — Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid ... Read More
FDA Approves Update to Gilteritinib AML Label to Include OS ... | 合法藥品大搜索
2019年5月30日 — Gilteritinib was initially approved by the FDA in November 2018; the decision was based on an interim analysis of CR/CRh rate, duration of CR/ ... Read More
Xospata (Gilteritinib) First Drug Approved as Monotherapy for ... | 合法藥品大搜索
由 LA Raedler 著作 — On November 28, 2018, the FDA approved oral gilteritinib (Xospata; Astellas Pharma), a tyrosine kinase inhibitor of several receptor kinases, including FLT3 ... Read More
相關資訊整理
【泰息安 膠囊 200 毫克】新確診之慢性期費城染色體陽性的慢性骨髓性白血病兒童病人。治療慢性期及加速期費城染色體(Philadelphia chromosome)陽性的慢性骨髓性白血病(Ph+CML)成年病人，且該病人至少有過一次對先前的治療(包括imatinib)有抗藥性或耐受性不良的經驗。具抗藥性或耐受性不良之慢性期費城染色體陽性的慢性骨髓細胞白血病兒童病人。
藥品名稱:泰息安膠囊200毫克許可證字號:衛署藥輸字第024834號許可證種類:製 劑適應症:新確診之慢性期費城染色體陽性的慢性...
【療德妥軟膠囊25毫克】於新確診為FLT3突變陽性的急性骨髓性白血病(AML)成人病患之標準前導(daunorubicin併用cytarabine)與鞏固性化療(高劑量cytarabine)時合併使用Rydapt。
藥品名稱:療德妥軟膠囊25毫克許可證字號:衛部藥輸字第027426號許可證種類:製 劑適應症:於新確診為FLT3突變陽性的急性骨髓性...
【樂拿舒注射劑】急性白血病（包括由慢性白血病轉變成急性者）惡性淋巴腫
藥品名稱:樂拿舒注射劑許可證字號:衛署藥輸字第018780號許可證種類:製 劑適應症:急性白血病（包括由慢性白血病轉變成急性者...
【泰息安膠囊150毫克】新確診之慢性期費城染色體陽性的慢性骨髓性白血病成年及兒童病人。具抗藥性或耐受性不良之慢性期費城染色體陽性的慢性骨髓細胞白血病兒童病人。
藥品名稱:泰息安膠囊150毫克許可證字號:衛署藥輸字第025317號許可證種類:製 劑適應症:新確診之慢性期費城染色體陽性的慢性...
【富樂舒注射劑】風濕性關節炎、骨關節炎、關節強直性脊椎炎、痛風
藥品名稱:富樂舒注射劑許可證字號:衛署藥輸字第016022號許可證種類:製 劑適應症:風濕性關節炎、骨關節炎、關節強直性脊椎炎...
【樂拿舒注射劑 10,000 K.U.】急性白血病（包括由慢性白血病轉變成急性者）惡性淋巴腫。
藥品名稱:樂拿舒注射劑10,000K.U.許可證字號:衛署藥輸字第021032號許可證種類:製 劑適應症:急性白血病（包括由慢性白血病轉...
【舒達定糖衣錠１１０公絲】抗炎消腫
藥品名稱:舒達定糖衣錠１１０公絲許可證字號:衛署藥輸字第007218號許可證種類:製 劑適應症:抗炎消腫劑型:藥品類別:須由醫師...